Vertex Pharmaceuticals: Q4 Earnings Insights

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell 1.1% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 47.65% year over year to $2.51, which missed the estimate of $2.59.

Revenue of $1,628,000,000 rose by 29.51% year over year, which beat the estimate of $1,580,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Feb 01, 2021

Time: 04:30 PM

ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1422591&tp_key=ff479c3073

Technicals

52-week high: $306.08

52-week low: $197.47

Price action over last quarter: Up 8.71%

Company Overview

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.